Risk stratification for PML in patients treated with Tysabri
Risk stratification for PML in patients treated with Tysabri
Abstract
Natalizumab is a highly effective immunomodulator in the treatment of multiple sclerosis (MS).
Treatment with natalizumab has been associated with progressive multifocal leukoencephalopathy (PML), an infection of the central nervous system (CNS) caused by a pathogenic form of the normally benign JC virus (JCV).
We searched PubMed and used current data from the natalizumab global safety database to assess risk factors and quantify the risk of PML.... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1768
MS-UK - http://www.ms-uk.org/
-
- Similar Topics
- Replies
- Views
- Last post
-
- 0 Replies
- 2173 Views
-
Last post by NHE
-
- 6 Replies
- 4698 Views
-
Last post by ElliotB
-
- 0 Replies
- 1277 Views
-
Last post by NHE
-
- 0 Replies
- 1559 Views
-
Last post by NHE
-
- 0 Replies
- 3243 Views
-
Last post by NHE
-
- 0 Replies
- 3033 Views
-
Last post by NHE
-
- 0 Replies
- 1255 Views
-
Last post by NHE
-
- 1 Replies
- 1420 Views
-
Last post by NHE
-
- 11 Replies
- 3212 Views
-
Last post by NHE